Published in Clin Cancer Res on June 01, 2005
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer (2010) 5.82
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 4.98
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest (2008) 4.95
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer (2011) 3.55
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol (2008) 2.85
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A (2009) 2.84
Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg (2007) 2.37
Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer (2011) 2.34
Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg (2007) 2.30
Gastrointestinal stromal tumors. Virchows Arch (2010) 2.28
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A (2006) 2.13
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer (2008) 1.99
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99
Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg (2006) 1.95
Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discov (2015) 1.65
Converting cancer therapies into cures: lessons from infectious diseases. Cell (2012) 1.65
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol (2011) 1.43
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol (2011) 1.42
Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A (2006) 1.42
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res (2009) 1.42
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res (2009) 1.37
Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. J Clin Invest (2007) 1.31
Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer (2011) 1.31
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle (2009) 1.29
The GIST paradigm: lessons for other kinase-driven cancers. J Pathol (2010) 1.26
ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol (2012) 1.21
Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol (2009) 1.21
KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J Exp Med (2013) 1.18
Genetic aberrations of gastrointestinal stromal tumors. Cancer (2008) 1.18
mTOR pathway in colorectal cancer: an update. Oncotarget (2014) 1.15
Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res (2009) 1.13
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer (2008) 1.13
Advances in the surgical management of gastrointestinal stromal tumor. Adv Surg (2011) 1.10
Gastrointestinal stromal tumors: past, present, and future. J Gastroenterol (2008) 1.09
Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol (2010) 1.08
Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov (2011) 1.07
Dynamics of targeted cancer therapy. Trends Mol Med (2012) 1.07
Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Mol Cancer Ther (2012) 1.07
Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β. Mol Cancer Ther (2011) 1.05
G-quadruplex-binding benzo[a]phenoxazines down-regulate c-KIT expression in human gastric carcinoma cells. J Am Chem Soc (2011) 1.05
Targeting cancer with kinase inhibitors. J Clin Invest (2015) 1.05
Management of resectable gastrointestinal stromal tumor. Hematol Oncol Clin North Am (2009) 1.03
Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol (2009) 1.03
Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer (2011) 1.02
Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer (2007) 1.01
Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol (2014) 1.00
An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol (2006) 1.00
Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol (2011) 0.99
GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). Cancer Chemother Pharmacol (2014) 0.99
Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res (2010) 0.98
Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clin Cancer Res (2014) 0.97
Emerging Roles of SIRT1 in Cancer Drug Resistance. Genes Cancer (2013) 0.97
Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med (2009) 0.97
Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin Cancer Res (2013) 0.97
Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood (2015) 0.97
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. BMC Cancer (2012) 0.97
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res (2009) 0.95
A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle (2010) 0.95
Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer (2006) 0.95
Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proc Natl Acad Sci U S A (2014) 0.94
The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting. J Transl Med (2011) 0.94
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. Biologics (2010) 0.93
Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors. Curr Genomics (2006) 0.93
Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy. Am J Surg Pathol (2013) 0.92
Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors. Appl Clin Genet (2010) 0.91
Gastrointestinal stromal tumors: molecular mechanisms and targeted therapies. Patholog Res Int (2011) 0.91
Role of receptor tyrosine kinases and their ligands in glioblastoma. Cells (2014) 0.91
Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants. PLoS One (2013) 0.90
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther Clin Risk Manag (2008) 0.90
Gastrointestinal tumors of the colon and rectum. Clin Colon Rectal Surg (2011) 0.89
Updates on the management of gastrointestinal stromal tumors. Surg Oncol Clin N Am (2012) 0.89
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations. PLoS One (2013) 0.88
Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn (2006) 0.88
Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol (2008) 0.88
Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A (2012) 0.87
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. Cancer Res (2015) 0.87
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br J Cancer (2013) 0.87
Clinical implications of mutational analysis in gastrointestinal stromal tumours. Br J Cancer (2008) 0.87
Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors. Oncotarget (2010) 0.86
Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene (2013) 0.86
CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. Genes Chromosomes Cancer (2011) 0.85
Gastrointestinal stromal tumor: a bridge between bench and bedside. Gastric Cancer (2010) 0.85
KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance. Gastric Cancer (2014) 0.85
Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS). Oncotarget (2015) 0.85
Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status. Hum Pathol (2010) 0.84
Frequent KIT mutations in human gastrointestinal stromal tumors. Sci Rep (2014) 0.84
Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. J Med Genet (2006) 0.84
Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment. Gastric Cancer (2006) 0.84
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature (2002) 10.96
Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell (2002) 9.36
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg (2002) 8.30
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science (2002) 6.32
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Clinicopathologic correlates of solitary fibrous tumors. Cancer (2002) 5.96
Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell (2003) 5.31
Crystal structure of the Bcl-XL-Beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein. J Biol Chem (2007) 5.21
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature (2008) 4.87
Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol (2005) 4.79
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell (2005) 4.73
Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med (2006) 4.71
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg (2003) 4.25
Quality of complication reporting in the surgical literature. Ann Surg (2002) 4.21
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol (2010) 4.01
Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med (2007) 3.79
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol (2002) 3.60
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol (2003) 3.56
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer (2008) 3.10
Structure of the protein phosphatase 2A holoenzyme. Cell (2006) 3.07
Structural analysis of a rhomboid family intramembrane protease reveals a gating mechanism for substrate entry. Nat Struct Mol Biol (2006) 3.00
Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J (2005) 2.99
Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg (2010) 2.99
Electronic synoptic operative reporting: assessing the reliability and completeness of synoptic reports for pancreatic resection. J Am Coll Surg (2010) 2.98
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg (2004) 2.86
Structural insights into the regulatory particle of the proteasome from Methanocaldococcus jannaschii. Mol Cell (2009) 2.75
A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J (2005) 2.71
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature (2010) 2.65
Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg (2004) 2.62
Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci U S A (2009) 2.57
Surgical treatment and outcomes of patients with primary inferior vena cava leiomyosarcoma. J Am Coll Surg (2003) 2.54
Adult spermatic cord sarcomas: management and results. Ann Surg Oncol (2003) 2.52
Ligand-induced asymmetry in histidine sensor kinase complex regulates quorum sensing. Cell (2006) 2.48
Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg (2002) 2.47
Structural basis of UV DNA-damage recognition by the DDB1-DDB2 complex. Cell (2008) 2.47
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res (2002) 2.41
Gastrointestinal stromal tumor: 5 years later. Cancer (2005) 2.40
Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol (2011) 2.39
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol (2002) 2.39
Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg (2005) 2.38
Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg (2007) 2.37
Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg (2003) 2.36
Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. PLoS Biol (2006) 2.35
Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer (2011) 2.34
The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery (2002) 2.32
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res (2003) 2.32
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet (2013) 2.30
Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol (2006) 2.30
Operative drainage following pancreatic resection: analysis of 1122 patients resected over 5 years at a single institution. Ann Surg (2013) 2.29